{
    "2018-01-22": [
        [
            {
                "time": "2018-02-06",
                "original_text": "Behind Novartis’s 4Q17 Estimates: Innovative Medicines",
                "features": {
                    "keywords": [
                        "Novartis",
                        "4Q17 Estimates",
                        "Innovative Medicines"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-06",
                "original_text": "Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth",
                "features": {
                    "keywords": [
                        "Novartis",
                        "4Q17 Earnings",
                        "Revenue Growth"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}